Cytokinetics Inc (CYTK) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cytokinetics Inc stock (CYTK) is currently trading at $62.39. Cytokinetics Inc PS ratio (Price-to-Sales) is 83.97. Analyst consensus price target for CYTK is $91.89. WallStSmart rates CYTK as Sell.
- CYTK PE ratio analysis and historical PE chart
- CYTK PS ratio (Price-to-Sales) history and trend
- CYTK intrinsic value — DCF, Graham Number, EPV models
- CYTK stock price prediction 2025 2026 2027 2028 2029 2030
- CYTK fair value vs current price
- CYTK insider transactions and insider buying
- Is CYTK undervalued or overvalued?
- Cytokinetics Inc financial analysis — revenue, earnings, cash flow
- CYTK Piotroski F-Score and Altman Z-Score
- CYTK analyst price target and Smart Rating
Cytokinetics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Cytokinetics Inc (CYTK) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Cytokinetics Inc (CYTK) Key Strengths (2)
114.52% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Cytokinetics Inc (CYTK) Areas to Watch (6)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Very expensive at 84.0x annual revenue
Very expensive at 60.3x book value
Revenue growing slowly at 4.90% annually
Supporting Valuation Data
Cytokinetics Inc (CYTK) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 8.5/10) while 6 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (83.97), Price/Book (60.31) suggest expensive pricing. Growth concerns include Revenue Growth at 4.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -572.00%, Operating Margin at -1005.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -572.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 4.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CYTK Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CYTK's Price-to-Sales ratio of 83.97x trades at a 40% premium to its historical average of 59.9x (79th percentile). The current valuation is 74% below its historical high of 329.22x set in Feb 2007, and 2414% above its historical low of 3.34x in Nov 2010.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cytokinetics Inc (CYTK) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Cytokinetics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 88M with 5% growth year-over-year.
Key Findings
Spending 115% of revenue (102M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -148M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Cytokinetics Inc.
Bottom Line
Cytokinetics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(58 last 3 months)
| Insider | Type | Shares |
|---|---|---|
CALLOS, ANDREW EVP, Chief Commercial Officer | Sell | -1,930 |
| Insider | Type | Shares |
|---|---|---|
CALLOS, ANDREW EVP, Chief Commercial Officer | Sell | -1,709 |
| Insider | Type | Shares |
|---|---|---|
CALLOS, ANDREW EVP, Chief Commercial Officer | Sell | -1,809 |
Data sourced from SEC Form 4 filings
Last updated: 3:02:13 PM
About Cytokinetics Inc(CYTK)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.